Rahel Laager

Ms. Rahel Laager

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
CWCarla Wunderle
Carla Wunderle
LHLuana Haller
Luana Haller
RLRahel Laager
Rahel Laager
LBLuca Bernasconi
Luca Bernasconi
PNPeter Neyer
Peter Neyer
PSPhilipp Schuetz
Philipp Schuetz
Lysine, methionine, and threonine are essential amino acids with vital functions for muscle and connective tissue health, metabolic balance, and the immune system. During illness, the demand for these amino acids typically increases, which puts patients at risk for deficiencies with harmful clinical consequences. In a secondary analysis of the Effect of Early Nutritional Support on Frailty, Functional Outcomes, and Recovery of Malnourished Medical Inpatients Trial (EFFORT), which compared individualized nutritional support to usual care nutrition in patients at nutritional risk, we investigated the prognostic impact of the lysine, methionine, and threonine metabolism. We had complete clinical and amino acid data in 237 patients, 58 of whom reached the primary endpoint of death at 30 days. In a model adjusted for comorbidities, sex, nutritional risk, and trial intervention, low plasma methionine levels were associated with 30-day mortality (adjusted HR 1.98 [95% CI 1.16 to 3.36], p = 0.01) and with a decline in functional status (adjusted OR 2.06 [95% CI 1.06 to 4.01], p = 0.03). The results for lysine and threonine did not show statistically significant differences regarding clinical outcomes. These findings suggest that low levels of methionine may be critical during hospitalization among patients at nutritional risk. Further studies should investigate the effect of supplementation of methionine in this patient group to improve outcomes.

27 November 2024 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
HBHelene Buergler
Helene Buergler
CGClaudia Gregoriano
Claudia Gregoriano
RLRahel Laager
Rahel Laager
BMBeat Mueller
Beat Mueller
PSPhilipp Schuetz
Philipp Schuetz
AKAlexander Kutz
Alexander Kutz
The epidemiology of infective endocarditis (IE) is evolving, driven by an aging population and increased use of endovascular devices, and is associated with significant morbidity and mortality. This study aims to evaluate changes in microbiological trends and clinical outcomes in patients with IE over the past decade in Switzerland. This nationwide cohort study analyzed in-hospital claims data from patients hospitalized with IE in Switzerland between 2012 and 2021. We assessed incidence rates per 100,000 hospitalizations, categorizing them by common pathogens. The outcomes included in-hospital and 6-month mortality, admission to the intensive care unit (ICU), and length of hospital stay (LOS). Among 15,255 hospitalizations with IE, the annual number of cases increased from 1,361 in 2012 to 1,636 in 2021. The most frequently diagnosed pathogens were Staphylococcus aureus (increasing from 19.8% to 30.0%, ptrend <0.01) and Streptococcus species (from 17.6% to 24.4%, ptrend <0.01). Infective endocarditis caused by Staphylococcus aureus was associated with the highest in-hospital (19.9%) and 6-month mortality (30.3%), and ICU admission rates (44.2%), with no relevant changes over time. The longest LOS was observed in hospitalizations with IE caused by Enterococcus species (mean 23.9 days) and Staphylococcus aureus (23.8 days). This nationwide cohort study showed an increase in IE hospitalizations from 2012 to 2021, primarily due to Staphylococcus aureus and Streptococcus species. Predominantly, Staphylococcus aureus was associated with adverse outcomes that remained consistently high over time compared to other or unidentified pathogens.

3 September 2024 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
RLRahel Laager
Rahel Laager
CGClaudia Gregoriano
Claudia Gregoriano
SHStephanie Hauser
Stephanie Hauser
HKHenrik Koehler
Henrik Koehler
PSPhilipp Schuetz
Philipp Schuetz
AKAlexander Kutz
Alexander Kutz
In Switzerland, all newborns undergo a systematic screening for lip and palate defects1,2 if these are not seen during prenatal ultrasonographic examination.3,4 Cleft lip or palate is among the most prevalent birth defects, with an incidence of approximately 1 to 2 per 1000 newborns and may be an early indication of a congenital malformation or associated syndromes.5-7 Nonetheless, 45% of cleft palates and 60% of cleft lips are diagnosed without any associated syndrome.6,8 Beyond feeding complications, long-term speech issues, sleep apnea, and hearing problems, cleft lip or palate has been identified as a risk factor for bronchiolitis.9-11 However, the link between these defects and other airway infections remains poorly explored. Furthermore, an association of the severity of cleft lip or palate with the need for hospitalization remains unexplored and may be an important factor for ambulatory pediatricians and family doctors to decide on a referral to the emergency department. Additionally, data on the association of corrective surgery with hospitalization risk and in-hospital resource use are scarce.12 The type of cleft dictates the method and timing of corrective surgery,13,14 with guidelines typically adhering to the Rule of 10s for lip repair: age at least 10 weeks, weight of 10 pounds, hemoglobin greater than 10 g/dL (to convert to grams per liter, multiply by 10), and white blood cell count exceeding 10 000 μL (to convert to ×109/L, multiply by 0.001).15,16 However, this rule does not account for the overall disease burden of cleft lip or palate and associated risks. Since hospitalizations for newborns or young children with cleft lip or palate typically require urgent care and a thorough interdisciplinary in-hospital work-up to prevent severe complications, understanding epidemiological trends and potential in-hospital adverse outcomes is therefore crucial.17 Hence, in this nationwide cohort study, our primary goal was to examine the incidence rates of hospitalizations due to respiratory infections or any cause during the first 2 years of life, considering the necessity and timing of corrective surgery. Our secondary aim was to assess clinical outcomes of newborns and young children with cleft lip or palate compared with those without clefts. Thus, this analysis aims to enhance our comprehension of the disease burden among hospitalized patients with cleft lip or palate.

1 June 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
NMNicole Meier
Nicole Meier
RLRahel Laager
Rahel Laager
CGClaudia Gregoriano
Claudia Gregoriano
PSPhilipp Schuetz
Philipp Schuetz
BMBeat Mueller
Beat Mueller
AKAlexander Kutz
Alexander Kutz
Objectives Novel antidiabetes medications with proven cardiovascular or renal benefit, such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RA), have been introduced to the market. This study explored the 4-year trends of antidiabetes medication use among medical hospitalisations with type 2 diabetes (T2D). Design Retrospective cohort study. Setting Tertiary care hospital in Switzerland. Participants 4695 adult hospitalisations with T2D and prevalent or incident use of one of the following antidiabetes medications (metformin, dipeptidyl peptidase-4 inhibitors (DPP-4i), sulfonylureas, GLP-1 RA, SGLT-2i, short-acting insulin or long-acting insulin), identified using electronic health record data. Quarterly trends in use of antidiabetes medications were plotted overall and stratified by cardiovascular disease (CVD) and chronic kidney disease (CKD). Results We observed a stable trend in the proportion of hospitalisations with T2D who received any antidiabetes medication (from 77.6% during 2019 to 78% in 2022; p for trend=0.97). In prevalent users, the largest increase in use was found for SGLT-2i (from 7.4% in 2019 to 21.8% in 2022; p for trend <0.01), the strongest decrease was observed for sulfonylureas (from 11.4% in 2019 to 7.2% in 2022; p for trend <0.01). Among incident users, SGLT-2i were the most frequently newly prescribed antidiabetes medication with an increase from 26% in 2019 to 56.1% in 2022 (p for trend <0.01). Between hospital admission and discharge, SGLT-2i also accounted for the largest increase in prescriptions (+5.1%; p<0.01). Conclusions These real-world data from 2019 to 2022 demonstrate a significant shift in antidiabetes medications within the in-hospital setting, with decreased use of sulfonylureas and increased prescriptions of SGLT-2i, especially in hospitalisations with CVD or CKD. This trend aligns with international guidelines and indicates swift adaptation by healthcare providers, signalling a move towards more effective diabetes management.

16 April 2025 in European Journal of Clinical Nutrition
Verified
Journal Article
Closed access
PDF file
PTPascal Tribolet
Pascal Tribolet
CWCarla Wunderle
Carla Wunderle
NKNina Kaegi-Braun
Nina Kaegi-Braun
LBLena Buchmueller
Lena Buchmueller
RLRahel Laager
Rahel Laager
PSPhilipp Schuetz
Philipp Schuetz

12 December 2025 in BMJ Open
Verified
Journal Article
Open access
HTHagena Thuraisingam
Hagena Thuraisingam
RLRahel Laager
Rahel Laager
CGClaudia Gregoriano
Claudia Gregoriano
PSPhilipp Schuetz
Philipp Schuetz
BMBeat Mueller
Beat Mueller
AKAlexander Kutz
Alexander Kutz
Importance: Postdischarge surveys are critical in collecting patient-reported experience measures (PREMs) and patient-reported outcome measures (PROMs), but response rates vary and are often low. Objective: To assess determinants that are associated with survey completion by phone in a complex medical care setting. Design: Secondary analysis of a prospective controlled interrupted time series analysis. Setting: As part of the non-randomised controlled In-HospiTOOL trial, a survey was conducted to gather data on PREMs and PROMs in multimorbid patients from seven hospitals in Switzerland. Participants: 31 103 medical acute care hospitalisations among seven intervention hospitals who were eligible for the survey. Interventions: Over a 6-month pre-intervention phase (August 2017 through January 2018) and a subsequent 12-month intervention phase (February 2018 through January 2019), patients were contacted by phone 30 days after hospital admission. Main outcomes and measures: The primary outcome was responsiveness to the survey. We assessed group differences between responders and non-responders, and associations of patient characteristics with survey completion were estimated using generalised estimating equations. Results: Of 31 103 eligible patients, 25 557 (82.2%) completed the survey 30 days after hospital admission. Responders were marginally older than non-responders (median (IQR) age, 73 (60–82) years vs 72 (57–82); standardised mean difference (SMD), −0.08), were more likely to be Swiss (81.9% vs 74.4%; SMD, −0.18), to have private healthcare insurance (22.9% vs 17.9%; SMD, 0.12), to be living at home before admission (85.7% vs 78.6%; SMD, 0.18) and to be less frail (67.4% vs 59.1%; SMD, 0.18). A longer length of stay (OR 0.98; 95% CI 0.97 to 0.99), discharge to a non-home institution (OR 0.50; 95% CI 0.46 to 0.54) and rehospitalisation within 30 days (OR 0.78; 95% CI 0.68 to 0.89) is associated with a decreased responsiveness. Conclusions: The study shows that achieving a high survey response rate among vulnerable acute care patients is feasible, which in turn allows for the effective identification of key determinants and enhances the collection of information on patients’ experiences and outcomes. Trial registration number: ISRCTN83274049 .